Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Vanda Pharmaceuticals Inc. earnings conference call. [Operator instructions] I would now like to hand the conference over to ...
The biotech's sleep drug Hetlioz gained an expanded approval. One of the hallmarks of SMS is that patients have a hard time sleeping during the night. It's a fairly rare disease -- Vanda estimates ...
WASHINGTON, May 6, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020. "Our strong ...
News of an update from the U.S. Food and Drug Administration (FDA) pushed Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares sharply higher early Wednesday. Essentially, the agency approved Vanda’s ...
WASHINGTON , Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug ...
Vanda Pharmaceuticals (VNDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.21 per share a year ago.
WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The D.C. biotech grew revenue for its products — in a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Supreme Court ruling ensures Vanda’s ability to ...
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Vanda Pharmaceuticals Inc. Earnings Conference Call. At this time all participants are in a listen-only mode. (Operator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback